ProKidney Corp. (PROK)
| Bid | 1 |
| Market Cap | 293.17M |
| Revenue (ttm) | 10.39M |
| Net Income (ttm) | -105.45M |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | -1.86 |
| Forward PE | -2.7 |
| Analyst | Hold |
| Ask | 1.01 |
| Volume | 1,344,268 |
| Avg. Volume (20D) | 454,381 |
| Open | 1.09 |
| Previous Close | 1.09 |
| Day's Range | 0.98 - 1.10 |
| 52-Week Range | 0.98 - 4.44 |
| Beta | 1.48 |
About PROK
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was fo...
Analyst Forecast
According to 5 analyst ratings, the average rating for PROK stock is "Hold." The 12-month stock price forecast is $4.5, which is an increase of 347.76% from the latest price.
1 month ago · seekingalpha.com
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD TreatmentRilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as we...